-
Functional control of myosin motors in the cardiac cycle Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-19 Malcolm Irving
-
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-19 Paul D. Morris, Ryan A. Anderton, Karina Marshall-Goebel, Joseph K. Britton, Stuart M. C. Lee, Nicolas P. Smith, Frans N. van de Vosse, Karen M. Ong, Tom A. Newman, Daniel J. Taylor, Tim Chico, Julian P. Gunn, Andrew J. Narracott, D. Rod Hose, Ian Halliday
-
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors Basic Res. Cardiol. (IF 7.5) Pub Date : 2024-07-17 Tamás G. Gergely, Zsófia D. Drobni, Nabil V. Sayour, Péter Ferdinandy, Zoltán V. Varga
-
Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives Eur. Heart J. (IF 37.6) Pub Date : 2024-07-19 Ulf Landmesser, Carsten Skurk, Apostolos Tzikas, Volkmar Falk, Vivek Y Reddy, Stephan Windecker
Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism
-
Genetic testing in early-onset atrial fibrillation Eur. Heart J. (IF 37.6) Pub Date : 2024-07-19 Shinwan Kany, Sean J Jurgens, Joel T Rämö, Ingrid E Christophersen, Michiel Rienstra, Mina K Chung, Morten S Olesen, Michael J Ackerman, Elizabeth M McNally, Christopher Semsarian, Renate B Schnabel, Arthur A M Wilde, Emelia J Benjamin, Heidi L Rehm, Paulus Kirchhof, Connie R Bezzina, Dan M Roden, M Benjamin Shoemaker, Patrick T Ellinor
Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed
-
Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-19 Tafadzwa T J Kufazvinei, Jason Chai, Katherine A Boden, Keith M Channon, Robin P Choudhury
After myocardial infarction (MI), patients with type 2 diabetes have an increased rate of adverse outcomes, compared to patients without. Diabetes confers a 1.5–2-fold increase in early mortality and, importantly, this discrepancy has been consistent over recent decades, despite advances in treatment and overall survival. Certain assumptions have emerged to explain this increased risk, such as differences
-
-
Predictors of the efficacy of His bundle pacing in patients with a prolonged PR interval: A stratified analysis of the HOPE‐HF randomized controlled trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-18 Daniel Keene, Nandita Kaza, Divya Srinivasan, Nadine Ali, Mark Tanner, Paul Foley, Badri Chandrasekaran, Philip Moore, Shaumik Adhya, Norman Qureshi, Amal Muthumala, Rebecca Lane, Aldo Rinaldi, Sharad Agarwal, Francisco Leyva, Jonathan Behar, Sukh Bassi, Andre Ng, Paul Scott, Rachana Prasad, Jon Swinburn, Joseph Tomson, Amarjit Sethi, Jaymin Shah, Phang Boon Lim, Andreas Kyriacou, Dewi Thomas, Jenny
AimsThe randomized, double‐blind, placebo‐controlled HOPE‐HF trial assessed the benefit of atrio‐ventricular (AV) delay optimization delivered using His bundle pacing. It recruited patients with left ventricular ejection fraction ≤40%, PR interval ≥200 ms, and baseline QRS ≤140 ms or right bundle branch block. Overall, there was no significant increase in peak oxygen uptake (VO2max) but there was significant
-
Catheter‐based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA‐HFPEF‐DZHK27 trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-18 Abdul S. Parwani, Stefan Kääb, Tim Friede, Roland Richard Tilz, Johann Bauersachs, Norbert Frey, Gerhard Hindricks, Thorsten Lewalter, Michiel Rienstra, Andreas Rillig, Daniel Scherr, Daniel Steven, Paulus Kirchhof, Burkert Pieske
AimsAtrial fibrillation (AF) is common in heart failure (HF) and negatively impacts outcomes. The role of ablation‐based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) is not known. The CABA‐HFPEF‐DZHK27 (CAtheter‐Based Ablation of atrial fibrillation compared to conventional treatment in patients with Heart Failure with Preserved Ejection
-
Reply to ‘Sex hormones and heart failure’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-18 Jungeun Lim, Jason Y.Y. Wong
-
CircARCN1 aggravates atherosclerosis by regulating HuR-mediated USP31 mRNA in macrophages Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-18 Zhicheng Pan, Jialan Lv, Liding Zhao, Kaidi Xing, Runze Ye, Yuesheng Zhang, Siyuan Chen, Peng Yang, Hailong Yu, Yangkai Lin, Ruobing Li, Dongfei Wang, Juan Fang, Yang Dong, Jianpeng Sheng, Xiaolin Wang, Ge Shan, Shan Zhang, Hongqiang Cheng, Qingbo Xu, Xiaogang Guo
Aims Circular RNAs (circRNAs) are considered important regulators of biological processes, but their impact on atherosclerosis development, a key factor in coronary artery disease (CAD), has not been fully elucidated. We aimed to investigate their potential use in patients with CAD and the pathogenesis of atherosclerosis. Methods and Results Patients with stable angina (SA) or acute coronary syndrome
-
Extra-domain A containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-18 Isabell Singerer, Laura Tempel, Katja Gruen, Judith Heiß, Clara Gutte, Mattia Matasci, Andrea Schrepper, Reinhard Bauer, Alexander Berndt, Christian Jung, P Christian Schulze, Dario Neri, Marcus Franz
Aims Pulmonary vascular and right ventricular remodelling processes are important for development and progression of pulmonary hypertension (PH). The current study analyzed the functional role of the extra domain A containing fibronectin (ED-A+ Fn) for the development of PH by comparing ED-A+ Fn knockout (KO) and wild-type (WT) mice as well as the effects of an antibody-based therapeutical approach
-
Dietary patterns to promote cardiometabolic health Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-17 Neha J. Pagidipati, Pam R. Taub, Robert J. Ostfeld, Carol F. Kirkpatrick
-
Bleeding risk prediction after acute myocardial infarction-integrating cancer data: the updated PRECISE-DAPT cancer score Eur. Heart J. (IF 37.6) Pub Date : 2024-07-17 Mohamed Dafaalla, Francesco Costa, Evangelos Kontopantelis, Mario Araya, Tim Kinnaird, Antonio Micari, Haibo Jia, Gary S Mintz, Mamas A Mamas
Background and Aims This study assessed the impact of incorporating cancer as a predictor on performance of the PRECISE-DAPT score. Methods A nationally linked cohort of ST-elevation myocardial infarction patients between 1 January 2005 and 31 March 2019 was derived from the UK Myocardial Ischaemia National Audit Project and the UK Hospital Episode Statistics Admitted Patient Care registries. The primary
-
Dilemmas in recommending exercise for prevention of heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Edimar Alcides Bocchi, Bruno Biselli, Guilherme Veiga Guimarães
-
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Alexander C. Egbe, Yogesh N.V. Reddy, Ahmed E. Ali, Ahmed Younis, Barry A. Borlaug
AimsThere are similarities in the pathogenesis of cardiac remodelling and dysfunction in heart failure with preserved ejection fraction (HFpEF) and coarctation of aorta (COA). We hypothesized that clinical HFpEF would be highly prevalent in adults with COA, and that the presence of HFpEF would increase the risk of mortality in this population. The aim of this study was to define the clinical features
-
Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics? Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Pierpaolo Pellicori, Joe J. Cuthbert, Andrew L. Clark, John G.F. Cleland
-
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Yogesh N.V. Reddy, Varun Sundaram
-
Diabetic myocardial disorder – a complex interaction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Katharina Marx‐Schütt, Jan Biegus
-
Association of baseline and longitudinal changes in insulin‐like growth factor‐binding protein‐7 with the risk of incident heart failure: Data from the PREVEND study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Sabrina Abou Kamar, Valentina Bracun, Maissa El‐Qendouci, Nils Bomer, Stephan J.L. Bakker, Ron T. Gansevoort, Eric Boersma, Isabella Kardys, Rudolf A. de Boer, Navin Suthahar
-
Pulmonary congestion assessed by lung ultrasound in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: Prevalence and prognostic implications Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Rosa Lillo, Stefano Cangemi, Francesca Graziani, Gabriella Locorotondo, Daniela Pedicino, Cristina Aurigemma, Enrico Romagnoli, Silvia Malara, Maria Chiara Meucci, Giulia Iannaccone, Francesco Bianchini, Marialisa Nesta, Piergiorgio Bruno, Antonella Lombardo, Carlo Trani, Francesco Burzotta
-
Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-17 Benoit J. Arsenault, Krithika Loganath, Arnaud Girard, Simona Botezatu, Kang H. Zheng, Evangelos Tzolos, Kathia Abdoun, Lionel Tastet, Romain Capoulade, Nancy Côté, Neil Craig, Kwan L. Chan, James W. Tam, Koon K. Teo, Christian Couture, Marie-Annick Clavel, Patrick Mathieu, Sébastien Thériault, Erik S. G. Stroes, David E. Newby, Sotirios Tsimikas, Philippe Pibarot, Marc R. Dweck
ImportanceThere are currently no pharmacological treatments available to slow hemodynamic progression of aortic stenosis. Plasma lipoprotein(a) concentrations predict incident aortic stenosis but its association with hemodynamic progression is controversial.ObjectiveTo determine the association between plasma lipoprotein(a) concentrations and hemodynamic progression in patients with aortic stenosis
-
Lipoprotein(a) and Long-Term Plaque Progression, Low-Density Plaque, and Pericoronary Inflammation JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-17 Nick S. Nurmohamed, Emilie L. Gaillard, Shant Malkasian, Robin J. de Groot, Shirin Ibrahim, Michiel J. Bom, Yannick Kaiser, James P. Earls, James K. Min, Jeffrey Kroon, R. Nils Planken, Ibrahim Danad, Alexander R. van Rosendael, Andrew D. Choi, Erik S.G. Stroes, Paul Knaapen
ImportanceLipoprotein(a) (Lp[a]) is a causal risk factor for cardiovascular disease; however, long-term effects on coronary atherosclerotic plaque phenotype, high-risk plaque formation, and pericoronary adipose tissue inflammation remain unknown.ObjectiveTo investigate the association of Lp(a) levels with long-term coronary artery plaque progression, high-risk plaque, and pericoronary adipose tissue
-
Cardiac involvement in Chagas disease and African trypanosomiasis Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-15 Ester Cerdeira Sabino, Maria Carmo P. Nunes, Johannes Blum, Israel Molina, Antonio Luiz P. Ribeiro
-
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers Eur. Heart J. (IF 37.6) Pub Date : 2024-07-16 Richard T Carrick, Alessio Gasperetti, Alexandros Protonotarios, Brittney Murray, Mikael Laredo, Iris van der Schaaf, Dennis Dooijes, Petros Syrris, Douglas Cannie, Crystal Tichnell, Nisha A Gilotra, Chiara Cappelletto, Kristen Medo, Ardan M Saguner, Firat Duru, Robyn J Hylind, Dominic J Abrams, Neal K Lakdawala, Julia Cadrin-Tourigny, Mattia Targetti, Iacopo Olivotto, Maddalena Graziosi, Moniek Cox
Background and Aims Pathogenic desmoplakin (DSP) gene variants are associated with the development of a distinct form of arrhythmogenic cardiomyopathy known as DSP cardiomyopathy. Patients harbouring these variants are at high risk for sustained ventricular arrhythmia (VA), but existing tools for individualized arrhythmic risk assessment have proven unreliable in this population. Methods Patients from
-
Beneficial normalization of cardiac repolarization by carnitine in transgenic SQT1 rabbit models Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-16 Ilona Bodi, Lea Mettke, Konstantin Michaelides, Tibor Hornyik, Stefan Meier, Saranda Nimani, Stefanie Perez-Feliz, Ibrahim el-Battrawy, Heiko Bugger, Manfred Zehender, Michael Brunner, Jordi Heijman, Katja E Odening
Aims Short-QT-syndrome type 1 (SQT1) is a genetic channelopathy caused by gain-of-function variants in HERG underlying the rapid delayed-rectifier K+ current (IKr), leading to QT-shortening, ventricular arrhythmias, and sudden cardiac death. Data on efficient pharmaco-therapy for SQT1 are scarce. In patients with primary carnitine-deficiency, acquired-SQTS has been observed and rescued by carnitine-supplementation
-
High variability in assays of blood markers of collagen turnover in cardiovascular disease: Implications for research and clinical practice Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-09 Pawel Piotr Rubiś, Ewa Dziewięcka, Arantxa González, John G.F. Cleland
Fibrosis is a common feature of many chronic diseases, including heart failure, which can have deleterious effects on cardiac structure and function that are associated with adverse outcomes. By-products of collagen synthesis and degradation, such as carboxy- and amino-terminal pro- or telo-peptides of collagen type I and III (PICP, PINP, PIIINP, and CITP) have been extensively investigated as markers
-
Genetic deletion or pharmacologic inhibition of HDAC6 protects the heart against ischemia/reperfusion injury by limiting TNFα-induced mitochondrial injury in experimental diabetes Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-13 Shelley L Baumgardt, Juan Fang, Xuebin Fu, Yanan Liu, Zhengyuan Xia, Ming Zhao, Ling Chen, Rachana Mishra, Muthukumar Gunasekaran, Progyaparamita Saha, Joseph M Forbess, Zeljko J Bosnjak, Amadou KS Camara, Judy R Kersten, Edward B Thorp, Sunjay Kaushal, Zhi-Dong Ge
Aims The histone deacetylase 6 (HDAC6) inhibitor, tubastatin A, reduces myocardial ischemia/reperfusion injury (MIRI) in type 1 diabetic rats. It remains unclear whether HDAC6 regulates MIRI in type 2 diabetic animals. Diabetes augments activity of HDAC6 and generation of tumor necrosis factor α (TNFα) and impairs mitochondrial complex I (mCI). Here we examined how HDAC6 regulates TNFα production,
-
The attenuated hepatic clearance of propionate increases cardiac oxidative stress in propionic acidemia Basic Res. Cardiol. (IF 7.5) Pub Date : 2024-07-11 You Wang, Suhong Zhu, Wentao He, Hannah Marchuk, Eva Richard, Lourdes R. Desviat, Sarah P. Young, Dwight Koeberl, Takhar Kasumov, Xiaoxin Chen, Guo-Fang Zhang
-
Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study Eur. Heart J. (IF 37.6) Pub Date : 2024-07-12 You-Jung Choi, Jaehyun Lim, Sungho Bea, Jieun Lee, Jah Yeon Choi, Seung Young Rho, Dae-In Lee, Jin Oh Na, Hyung-Kwan Kim
Background and Aims Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. Methods This was a modified
-
Randomized 20-year infancy-onset dietary intervention, life-long cardiovascular risk factors and retinal microvasculature Eur. Heart J. (IF 37.6) Pub Date : 2024-07-12 Oskari Repo, Markus Juonala, Harri Niinikoski, Suvi Rovio, Juha Mykkänen, Hanna Lagström, Carol Y Cheung, Dawei Yang, Hanna Vaahtoranta-Lehtonen, Antti Jula, Jaakko Nevalainen, Tapani Rönnemaa, Jorma Viikari, Olli Raitakari, Robyn Tapp, Katja Pahkala
Background and Aims Retinal microvasculature characteristics predict cardiovascular morbidity and mortality. This study investigated associations of lifelong cardiovascular risk factors and effects of dietary intervention on retinal microvasculature in young adulthood. Methods The cohort is derived from the longitudinal Special Turku Coronary Risk Factor Intervention Project study. The Special Turku
-
European Society of Cardiology quality indicators update for the care and outcomes of adults with heart failure. The Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-12 Amr Abdin, Chris Wilkinson, Suleman Aktaa, Michael Böhm, Marija Polovina, Giuseppe Rosano, Mitja Lainscak, Lars H. Lund, Theresa McDonagh, Marco Metra, Marianna Adamo, Richard Mindham, Massimo Piepoli, Magdy Abdelhamid, Stefan Störk, Maria P. Tokmakova, Petar Seferović, Andrew J.S. Coats, Chris P. Gale
AimsTo update the European Society of Cardiology (ESC) quality indicators (QIs) for the evaluation of the care and outcomes of adults with heart failure.Methods and resultsThe Working Group comprised experts in heart failure including members of the ESC Clinical Practice Guidelines Task Force for heart failure, members of the Heart Failure Association, and a patient representative. We followed the
-
Consequences of ionizing radiation exposure to the cardiovascular system Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-10 James W. S. Jahng, Mark P. Little, Hyunsoo J. No, Billy W. Loo, Joseph C. Wu
-
Coronary artery disease management in older adults: revascularization and exercise training Eur. Heart J. (IF 37.6) Pub Date : 2024-07-10 Rita Pavasini, Simone Biscaglia, Vijay Kunadian, Abdul Hakeem, Gianluca Campo
The mean age of patients with coronary artery disease (CAD) is steadily increasing. In older patients, there is a tendency to underutilize invasive approach, coronary revascularization, up-to-date pharmacological therapies, and secondary prevention strategies, including cardiac rehabilitation. Older adults with CAD commonly exhibit atypical symptoms, multi-vessel disease involvement, complex coronary
-
Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice Eur. Heart J. (IF 37.6) Pub Date : 2024-07-10 Luis R Lopes, Carolyn Y Ho, Perry M Elliott
Pathogenic variation in genes encoding proteins of the cardiac sarcomere is responsible for 30%–40% of cases of hypertrophic cardiomyopathy. The main clinical utility of genetic testing is to provide diagnostic confirmation and facilitation of family screening. It also assists in the detection of aetiologies, which require distinct monitoring and treatment approaches. Other clinical applications, including
-
How, when, and who: Composing the puzzle of family screening in hereditary cardiac amyloidosis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-10 Giuseppe Limongelli, Giuseppe Palmiero
-
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-10 André Zimerman, Eugene Braunwald, Jan Steffel, Nicolas M. Van Mieghem, Michael G. Palazzolo, Sabina A. Murphy, Cathy Zi Li Chen, Martin Unverdorben, Christian T. Ruff, Elliott M. Antman, Robert P. Giugliano
ImportanceIn older patients with atrial fibrillation who take anticoagulants for stroke prevention, bleeding is increased compared with younger patients, thus, clinicians frequently prescribe lower than recommended doses in older patients despite limited randomized data.ObjectiveTo evaluate ischemic and bleeding outcomes in patients 80 years and older with atrial fibrillation receiving edoxaban, 60
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-10 Catherine P. Benziger, Amanda Stebbins, Lisa M. Wruck, Mark B. Effron, Guillaume Marquis-Gravel, Peter M. Farrehi, Saket Girotra, Kamal Gupta, Sunil Kripalani, Daniel Munoz, Tamar S. Polonsky, Amber Sharlow, Jeffrey Whittle, Robert A. Harrington, Russell L. Rothman, Adrian F. Hernandez, W. Schuyler Jones
ImportanceAtherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dosed daily at 81 mg or 325 mg in the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical
-
Plasma soluble fms‐like tyrosine kinase‐1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-09 Melinda A. Paterson, Anna P. Pilbrow, Chris M. Frampton, Vicky A. Cameron, Richard W. Troughton, Chris J. Pemberton, Mayanna Lund, Gerard P. Devlin, A. Mark Richards, Robert N. Doughty, Barry R. Palmer
-
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from EMPULSE Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-09 João Pedro Ferreira, Jonathan P. Blatchford, John R. Teerlink, Mikhail N. Kosiborod, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Jasper Tromp, Michael E. Nassif, Mitchell A. Psotka, Josep Comin‐Colet, Robert J. Mentz, Martina Brueckmann, Matias Nordaby, Piotr Ponikowski, Adriaan A. Voors
AimsPatients hospitalized for acute heart failure (HF) could be enrolled in EMPULSE (NCT04157751) upon haemodynamic stabilization and between 24 h and 5 days after hospital admission. The timing of treatment initiation may influence the efficacy and safety of drugs such as empagliflozin. The aim of this study was to evaluate patient characteristics, clinical events, and treatment effects according
-
Artificial intelligence-enhanced patient evaluation: bridging art and science Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Evangelos K Oikonomou, Rohan Khera
The advent of digital health and artificial intelligence (AI) has promised to revolutionize clinical care, but real-world patient evaluation has yet to witness transformative changes. As history taking and physical examination continue to rely on long-established practices, a growing pipeline of AI-enhanced digital tools may soon augment the traditional clinical encounter into a data-driven process
-
Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Iulia Iatan, Leo E Akioyamen, Isabelle Ruel, Amanda Guerin, Lindsay Hales, Thais Coutinho, Liam R Brunham, Jacques Genest
Background and Aims Familial hypercholesterolaemia (FH) is a highly prevalent monogenic disorder characterized by elevated LDL cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease. Sex disparities in diagnosis, lipid-lowering therapy, and achieved lipid levels have emerged worldwide, resulting in barriers to care in FH. A systematic review was performed to investigate sex-related
-
Lumican promotes calcific aortic valve disease through H3 histone lactylation Eur. Heart J. (IF 37.6) Pub Date : 2024-07-08 Yuming Huang, Chunli Wang, Tingwen Zhou, Fei Xie, Zongtao Liu, Haiying Xu, Ming Liu, Shunshun Wang, Lanqing Li, Qingjia Chi, Jiawei Shi, Nianguo Dong, Kang Xu
Background and Aims Valve interstitial cells (VICs) undergo a transition to intermediate state cells before ultimately transforming into the osteogenic cell population, which is a pivotal cellular process in calcific aortic valve disease (CAVD). Herein, this study successfully delineated the stages of VIC osteogenic transformation and elucidated a novel key regulatory role of lumican (LUM) in this
-
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention Cardiovasc. Res. (IF 10.2) Pub Date : 2024-07-06 Umidakhon Makhmudova, Elisabeth Steinhagen-Thiessen, Massimo Volpe, Ulf Landmesser
Nucleic acid-based therapies are being rapidly developed for prevention and management of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the delivery, safety, and effectiveness of these therapeutics in the past decade. These therapies can also modulate therapeutic targets that cannot be sufficiently addressed using traditional drugs or antibodies. Among the nucleic acid-targeted
-
The LDL cumulative exposure hypothesis: evidence and practical applications Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-07-05 Brian A. Ference, Eugene Braunwald, Alberico L. Catapano
-
Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-05 Vallerie V. McLaughlin, Olivier Sitbon, Kelly M. Chin, Nazzareno Galiè, Marius M. Hoeper, David G. Kiely, Gwen MacDonald, Nicolas Martin, Stephen C. Mathai, Andrew Peacock, Ahmed Tawakol, Adam Torbicki, Anton Vonk Noordegraaf, Stephan Rosenkranz
-
Bone marrow cells contribute to seven different endothelial cell populations in the heart Basic Res. Cardiol. (IF 7.5) Pub Date : 2024-07-04 Parisa Shabani, Vahagn Ohanyan, Ammar Alghadeer, Daniel Gavazzi, Feng Dong, Liya Yin, Christopher Kolz, Lindsay Shockling, Molly Enrick, Ping Zhang, Xin Shi, William Chilian
-
Iron deficiency and supplementation in patients with heart failure: Results from the IRON‐HF international survey Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-04 Massimiliano Camilli, Federico Ballacci, Valentina Alice Rossi, Antonio Cannatà, Luca Monzo, Nathan Mewton, Nicolas Girerd, Piero Gentile, Marco Marini, Massimo Mapelli, Andreas J. Flammer, Nadia Aspromonte, Rocco Antonio Montone, Antonella Lombardo, Gaetano Antonio Lanza, Gianluigi Savarese, Frank Ruschitzka, Filippo Crea
AimsIron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, regardless of anaemia status. Iron supplementation has been demonstrated to improve exercise capacity and quality of life in patients with HF with an ejection fraction <50% and ID. This survey aimed to provide data on real‐world practices related to ID screening and management.Methods and resultsWe
-
Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-04 Gaspard Suc, Bernard Iung
-
Hypoalbuminaemia and heart failure: A practical review of current evidence Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-04 Marta Biancucci, Riccardo Barbiero, Benedetta Pennella, Antonio Cannatà, Walter Ageno, Flavio Tangianu, Andrea Maria Maresca, Francesco Dentali, Aldo Bonaventura
Hypoalbuminaemia (serum albumin levels ≤3.5 g/dl) is associated with poor outcomes among patients with heart failure (HF). This narrative review includes original articles and reviews published over the past 20 years and retrieved from PubMed using the following search terms (or their combination): ‘heart failure’, ‘hypoalbuminaemia’, ‘heart failure with reduced ejection fraction’, ‘heart failure with
-
Combined tricuspid and left‐sided valvular heart disease: A frequent and treatable scenario Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-03 Giovanni Benfari, Paolo Springhetti, Maurice Enriquez‐Sarano
-
Why left atrial venting fails to influence extracorporeal life support survival in cardiogenic shock: Unravelling the intricate reality of unloading Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-03 Aurore Ughetto, Christophe Vandenbriele, Clément Delmas
Over the past decade, extracorporeal life support (ECLS) has gained increasing utilization in the management of refractory cardiogenic shock (CS) with a class IIaC recommendation according to the latest European and US guidelines.1 However, recent randomized controlled trials (RCTs) and meta-analyses can be considered inconclusive in demonstrating the benefit of ECLS compared with optimal medical treatment
-
Haemodynamic contributors to pulmonary hypertension across the spectrum of adult congenital heart disease Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-03 Yogesh N.V. Reddy, William R. Miranda, Christopher C. Jain, Barry A. Borlaug, Alexander C. Egbe
AimsAdult congenital heart disease (ACHD) includes multiple disease states that predispose to pulmonary hypertension (PH). Haemodynamically, PH depends on abnormalities in three components: pulmonary blood flow (Qp), pulmonary vascular resistance (PVR) and pulmonary venous pressure (PVP). We sought to evaluate the prevalence and prognostic impact of individual haemodynamic abnormalities in ACHD.Methods
-
Incidental Complication From a Left Atrial Appendage Device JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-03 Rimmy Garg, Sudhir Mungee, Rebecca Baumann
This case report describes a diagnosis of extracardiac mural thrombus and pulmonary emboli resulting from a left atrial appendage device in a patient with atrial fibrillation.
-
Large-Scale Proteomics in Early Pregnancy and Hypertensive Disorders of Pregnancy JAMA Cardiol. (IF 14.8) Pub Date : 2024-07-03 Philip Greenland, Mark R. Segal, Rebecca B. McNeil, Corette B. Parker, Victoria L. Pemberton, William A. Grobman, Robert M. Silver, Hyagriv N. Simhan, George R. Saade, Peter Ganz, Priya Mehta, Janet M. Catov, C. Noel Bairey Merz, Jasmina Varagic, Sadiya S. Khan, Samuel Parry, Uma M. Reddy, Brian M. Mercer, Ronald J. Wapner, David M. Haas
ImportanceThere is no consensus regarding the best method for prediction of hypertensive disorders of pregnancy (HDP), including gestational hypertension and preeclampsia.ObjectiveTo determine predictive ability in early pregnancy of large-scale proteomics for prediction of HDP.Design, Setting, and ParticipantsThis was a nested case-control study, conducted in 2022 to 2023, using clinical data and
-
Atrial fibrillation burden: a new outcome predictor and therapeutic target Eur. Heart J. (IF 37.6) Pub Date : 2024-07-02 Nina Becher, Andreas Metzner, Tobias Toennis, Paulus Kirchhof, Renate B Schnabel
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF burden and outcomes and potential effects of AF burden reduction. A lower AF burden
-
Wearable device-measured moderate to vigorous physical activity and risk of degenerative aortic valve stenosis Eur. Heart J. (IF 37.6) Pub Date : 2024-07-02 Ziang Li, Sijing Cheng, Bo Guo, Lu Ding, Yu Liang, Yinghan Shen, Jinyue Li, Yiqing Hu, Tianxin Long, Xinli Guo, Junbo Ge, Runlin Gao, Philippe Pibarot, Bin Zhang, Haiyan Xu, Marie-Annick Clavel, Yongjian Wu
Background and Aims Physical activity has proven effective in preventing atherosclerotic cardiovascular disease, but its role in preventing degenerative valvular heart disease (VHD) remains uncertain. This study aimed to explore the dose–response association between moderate to vigorous physical activity (MVPA) volume and the risk of degenerative VHD among middle-aged adults. Methods A full week of
-
Private Equity in Cardiovascular Practice: Solution or Symptom? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-30 Edward T.A. Fry MD
-
Private Equity Acquisitions of Outpatient Cardiology Practices in the United States, 2013-2023 J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-30 Victoria L. Bartlett MD, Michael Liu MPhil, Shylie Ati BA, Robert W. Yeh MD MSc, Zhaonian Zheng MSc, Rishi K. Wadhera MD MPP MPhil
-
Transcatheter treatment of pure aortic regurgitation Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-06-27 Marco Barbanti, Giulia Laterra, Francesco Maisano